Institutional Investor Sentiment About Chemocentryx Inc (NASDAQ:CCXI) Up

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Sentiment for Chemocentryx Inc (NASDAQ:CCXI)

Chemocentryx Inc (NASDAQ:CCXI) institutional sentiment decreased to 0.93 in Q4 2018. Its down -0.05, from 0.98 in 2018Q3. The ratio turned negative, as 42 funds started new and increased holdings, while 45 sold and decreased their stakes in Chemocentryx Inc. The funds in our partner’s database now possess: 27.13 million shares, up from 26.80 million shares in 2018Q3. Also, the number of funds holding Chemocentryx Inc in their top 10 holdings was flat from 1 to 1 for the same number . Sold All: 7 Reduced: 38 Increased: 24 New Position: 18.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $700.50 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

The stock decreased 4.82% or $0.61 during the last trading session, reaching $12.14. About 239,394 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 12.22% since May 8, 2018 and is uptrending. It has outperformed by 7.85% the S&P500.

Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on August, 8. They expect $-0.26 earnings per share, down 85.71 % or $0.12 from last year’s $-0.14 per share. After $-0.23 actual earnings per share reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts 13.04 % negative EPS growth.

Bvf Inc Il holds 9.54% of its portfolio in ChemoCentryx, Inc. for 6.69 million shares. P.A.W. Capital Corp owns 50,000 shares or 0.68% of their US portfolio. Moreover, Sio Capital Management Llc has 0.67% invested in the company for 169,257 shares. The Utah-based Wasatch Advisors Inc has invested 0.34% in the stock. Nantahala Capital Management Llc, a Connecticut-based fund reported 623,338 shares.

Since January 1, 0001, it had 0 insider purchases, and 5 sales for $1.38 million activity.

ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage

Ratings analysis reveals 100% of ChemoCentryx’s analysts are positive. Out of 5 Wall Street analysts rating ChemoCentryx, 5 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $20 while the high is $23. The stock’s average target of $21.25 is 75.04% above today’s ($12.14) share price. CCXI was included in 5 notes of analysts from November 12, 2018. On Thursday, February 14 the stock rating was initiated by Leerink Swann with “Buy”. The firm has “Buy” rating given on Tuesday, March 12 by H.C. Wainwright. The rating was upgraded by FBR Capital on Wednesday, March 27 to “Buy”. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Buy” rating by Canaccord Genuity on Monday, November 12.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: which released: “ChemoCentryx to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference – GlobeNewswire” on September 26, 2018, also with their article: “Report: Exploring Fundamental Drivers Behind Lincoln National, News Corporation, Macerich, ChemoCentryx, Delek Logistics Partners, and SunCoke Energy Partners — New Horizons, Emerging Trends, and Upcoming Developments – GlobeNewswire” published on April 16, 2019, published: “ChemoCentryx (CCXI) CEO Thomas Schall on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” on November 08, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: and their article: “ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights – GlobeNewswire” published on November 08, 2018 as well as‘s news article titled: “ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights – GlobeNewswire” with publication date: May 06, 2019.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.